Mumbai, Aug. 7 -- Zydus Lifesciences (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group's first NOC approval in Canada.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.